ESMO Open最新文献

{"title":"12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation","authors":"Z. Ianniello, E. Quijano, D.A. Colón-Ríos, M. Rackear, P.M. Glazer","doi":"10.1016/j.esmoop.2026.106115","DOIUrl":"10.1016/j.esmoop.2026.106115","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106115"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"32P Whole-slide histopathology embeddings enable non-genomic HER2 biomarker prediction in esophageal adenocarcinoma","authors":"K. Nijjer , A. Ahmed","doi":"10.1016/j.esmoop.2026.106136","DOIUrl":"10.1016/j.esmoop.2026.106136","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106136"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"98P Optimizing treatment for CDK4/6 inhibitor-resistant breast cancer using patient-derived models","authors":"B. Policastro , N. Nissen , M.K. Jakobsen , S. Ehmsen , O.L. Gammelgaard , F. Rosengren , L.E. Johansen , J. Staaf , H.J. Ditzel , C.L. Alves","doi":"10.1016/j.esmoop.2026.106240","DOIUrl":"10.1016/j.esmoop.2026.106240","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106240"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"111P EGFR and MET mRNA overexpression in non-small cell lung cancer: Prevalence and sensitivity to targeted therapies","authors":"S. Garcia-Roman , C. Aguado , E. Marin , C. Mayo de Las Casas , M. Garzón-Ibáñez , N. Jordana Ariza , R. Roman , E. Aldeguer , S. Muñoz , I. Sánchez , R. Reyes , M.F. García Casabal , R. Rosell , M.A. Molina-Vila","doi":"10.1016/j.esmoop.2026.106253","DOIUrl":"10.1016/j.esmoop.2026.106253","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106253"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE","authors":"J. Fayette ,&nbsp;C. Cropet ,&nbsp;C. Toullec ,&nbsp;M. Burgy ,&nbsp;A. Bruyas ,&nbsp;C. Sire ,&nbsp;A. Lagrange ,&nbsp;F. Clatot ,&nbsp;M. Vinches ,&nbsp;M. Iacob ,&nbsp;L. Martin ,&nbsp;M.-C. Kaminsky ,&nbsp;D. Vansteene ,&nbsp;S. Salas ,&nbsp;A. Champagnac ,&nbsp;P. Saintigny ,&nbsp;J. Gautier ,&nbsp;D. Pérol ,&nbsp;J. Bourhis","doi":"10.1016/j.esmoop.2026.106946","DOIUrl":"10.1016/j.esmoop.2026.106946","url":null,"abstract":"<div><h3>Background</h3><div>Pembrolizumab, combined with platinum-5-FU or as a monotherapy, is the standard treatment of patients with recurrent and/or metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC). This treatment is used exclusively in programmed death-ligand 1 (PD-L1)-positive patients in Europe, whereas it is used in the USA regardless of PD-L1 status. However, substantial toxicities, notably those related to cisplatin-based chemotherapy, preclude the use of combination therapy in fragile patients. We investigated the efficacy and tolerance of first-line durvalumab combined with weekly carboplatin/paclitaxel in R/M HNSCC patients who were ineligible for cisplatin.</div></div><div><h3>Patients and methods</h3><div>This prospective multicenter single-arm phase II study assessed tolerance in R/M HNSCC patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-1 (run-in phase study feasibility, then cohort A) and ECOG-PS 2 (cohort B), frail, not eligible for standard cisplatin-based chemotherapy. In the first-line, patients received four 28-day chemotherapy cycles (carboplatin AUC2; paclitaxel 80 mg/m² day 1, 8, and 15) combined with durvalumab 1500 mg every 4 weeks for 12 months maximum. The primary endpoint was 12-month overall survival (OS) rate based on a Fleming A’Hern design: cohort A, P₀ inefficacy boundary 47%, P₁ target efficacy 65%, at least 38 successes among 64 patients assessable were required for further investigations; cohort B: P₀ 15%; P₁ 35%, at least 10 successes needed among 38 patients to reject the null hypothesis.</div></div><div><h3>Results</h3><div>From 16 May 2019 to 4 March 2021, 64 patients with an ECOG-PS of 1 (cohort A) from 13 French authorized centers (hospital, cancer centers) were included and received study treatments. Cohort B enrolled 40 patients with an ECOG-PS of 2 from 25 Aug 2021 and 9 March 2023 and 39 were assessable. With 40 patients with an ECOG-PS of 0-1 [62.5%, unilateral 95% confidence interval (CI) 51.5%-∞], and 20 patients with an ECOG-PS of 2 (51.3%, unilateral 95% CI 37.1%-∞) alive at 12 months, the study met its primary endpoints.</div></div><div><h3>Conclusions</h3><div>The promising results in frail patients with an ECOG-PS of 0-1 and 2 encourages further investigation of durvalumab with weekly carboplatin/paclitaxel in first-line R/M HNSCC patients in a comparative phase III clinical trial.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106946"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY","authors":"B. Besse ,&nbsp;E. Felip ,&nbsp;B.C. Cho ,&nbsp;T. Takahashi ,&nbsp;K. Politi ,&nbsp;J. Wang ,&nbsp;G. De Castro Jr. ,&nbsp;A. Kowalczyk-Tekiela ,&nbsp;L. Bonanno ,&nbsp;A.S. Muntean ,&nbsp;G. Lo Russo ,&nbsp;J. Fuentes Pradera ,&nbsp;S.H. Kim ,&nbsp;M. Florescu ,&nbsp;P. Chen ,&nbsp;E. Pons-Tostivint ,&nbsp;Y. Chepka ,&nbsp;H. Mann ,&nbsp;J. Rogerio ,&nbsp;P.M. Forde","doi":"10.1016/j.esmoop.2026.106957","DOIUrl":"10.1016/j.esmoop.2026.106957","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106957"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147748465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: “Artificial intelligence-powered real-time multimodal model for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study”","authors":"N. Li ,&nbsp;X. Liu ,&nbsp;S. Zhang","doi":"10.1016/j.esmoop.2026.106943","DOIUrl":"10.1016/j.esmoop.2026.106943","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106943"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New prognostic and predictive scoring systems for colorectal cancer liver metastases","authors":"F. Salvà ,&nbsp;S. Pérez Fernandez ,&nbsp;C. Dopazo ,&nbsp;M. Salcedo ,&nbsp;N. Saoudi ,&nbsp;M. Rodriguez ,&nbsp;I. Baraibar ,&nbsp;J. Ros ,&nbsp;C. Salva de Torres ,&nbsp;C. Vaghi ,&nbsp;Z. Calixto ,&nbsp;C. Gómez-Gavara ,&nbsp;M. Caralt ,&nbsp;G. Sapisochin ,&nbsp;J. Tabernero ,&nbsp;E. Elez","doi":"10.1016/j.esmoop.2026.106923","DOIUrl":"10.1016/j.esmoop.2026.106923","url":null,"abstract":"<div><div>Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge, shaped by marked biological heterogeneity and unpredictable clinical outcomes. While classical Clinical Risk Scores (CRS) continue to inform surgical decision making, their static nature limits their relevance in an era defined by molecular profiling, dynamic biomarkers, and personalized therapy. Advances in genomics and liquid biopsy technologies have expanded the understanding of CRLM beyond traditional clinicopathological parameters, enabling real-time disease monitoring and more refined risk stratification. In parallel, dynamic scoring systems that incorporate evolving clinical and molecular data are redefining how risk is assessed and managed throughout the course of treatment. This review revisits classical CRS, explores emerging molecular and dynamic tools, and discusses their potential integration into clinical practice to improve patient selection, guide treatment timing, and refine the overall management of CRLM.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106923"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up†","authors":"S. Piperno-Neumann ,&nbsp;M. Angi ,&nbsp;P.A. Ascierto ,&nbsp;J.F. Baurain ,&nbsp;M.C. Burgmans ,&nbsp;N. Cassoux ,&nbsp;S.E. Coupland ,&nbsp;R. Dendale ,&nbsp;A. Fortuna ,&nbsp;L. Gastaud ,&nbsp;C. Gutierrez-Miguelez ,&nbsp;S. Heegaard ,&nbsp;M.J. Jager ,&nbsp;E. Kapiteijn ,&nbsp;U. Keilholz ,&nbsp;E. Kilic ,&nbsp;M. Marinkovic ,&nbsp;A. Moulin ,&nbsp;P. Nathan ,&nbsp;S.P. Patel ,&nbsp;O. Michielin","doi":"10.1016/j.esmoop.2026.106888","DOIUrl":"10.1016/j.esmoop.2026.106888","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106888"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147748179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LBA4 Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Final overall survival (OS) analysis from the randomized OptiTROP-Lung03 study","authors":"W.F. Fang ,&nbsp;X. Li ,&nbsp;Q. Wang ,&nbsp;X. Meng ,&nbsp;W. Zheng ,&nbsp;L. Sun ,&nbsp;W. Yao ,&nbsp;W. Zhuang ,&nbsp;Y. Fan ,&nbsp;M. Zhuo ,&nbsp;Y. Luo ,&nbsp;Z. Zhang ,&nbsp;X. Song ,&nbsp;R. Yang ,&nbsp;J. Yang ,&nbsp;Y. Diao ,&nbsp;J. Ge ,&nbsp;L. Zhang ,&nbsp;Y. Yang","doi":"10.1016/j.esmoop.2026.106960","DOIUrl":"10.1016/j.esmoop.2026.106960","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106960"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147748460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}